Pregnant women with COVID-19: new study tracks antibodies in moms and newborns

NCT ID NCT04659759

Completed Knowledge-focused Sponsor: Thomas Jefferson University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study followed 105 pregnant women who had COVID-19 or received a COVID-19 vaccine. Researchers measured antibodies in the mothers' blood and breast milk, as well as in the umbilical cord blood at delivery, to see how immunity transfers to the baby. The goal was to better understand protection for both mother and newborn up to 6 weeks after birth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could help doctors understand how COVID-19 antibodies pass from mother to baby and how long protection lasts after infection or vaccination.
What could go wrong: This is an observational study, not a treatment trial. It cannot prove whether vaccination or infection prevents illness in babies, and results may not apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID19

Contacts and locations

Locations

Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, 19107, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.